OakChart

Cabaletta Bio Inc

CABAHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 9:55 AM ET

1.43-0.02 (-1.03%)
2026-11-11 15:55 CET
Market cap
312.79 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-189.50 USD m
Free cash flow, TTM
-162.51 USD m
EPS diluted, TTM
-1.43
P/E
-
Compare

Price

CABA against its 20, 50 and 200-day averages
2050200beat
2.003.004.0012.1M24.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CABAclose 1.4420-day 1.4650-day 2.02200-day 2.811.44

66.1% under 4.23 on 6 May 2026. Last 15 sessions, 38.1% high to low

Profile

CABA
52-week range, 8% of the way up
1.184.23

Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.

IndexRUT
Employees156
IPOOct 25, 2019
Beta3.54
ATR, 14d0.14
Rel volume0.19
Short float20.12%
Insider own11.59%
Inst own71.67%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap309.55M
Enterprise Value33.34M
Income-189.50M
Sales0.00M
Book/sh1.32
Cash/sh1.39
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees156
IPOOct 25, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.09
P/C1.03
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio6.55
Current Ratio6.55
Debt/Eq0.08
LT Debt/Eq0.02
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.43
EPS next Y-1.06
EPS next Q-0.27
EPS this Y40.22%
EPS next Y15.79%
EPS next 5Y23.10%
EPS past 3/5Y-5.18% -7.84%
Sales past 3/5Y- -
EPS Y/Y TTM43.51%
Sales Y/Y TTM-
EPS Q/Q35.26%
Sales Q/Q-
EarningsNov 05 BMO
EPS/Sales Surpr.11.78% -

Ownership

Insider Own11.59%
Insider Trans0.00%
Inst Own71.67%
Inst Trans28.58%
ROA-72.02%
ROE-89.52%
ROIC-65.54%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-1.83%
SMA50-28.80%
SMA200-48.89%
Trades-

Technical

Shs Outstand215.72M
Shs Float190.72M
Short Float20.12%
Short Ratio7.24
Short Interest38.37M
52W High4.23 -66.08%
52W Low1.18 21.61%
Volatility11.74% 10.18%
ATR (14)0.14
RSI (14)40.61
Beta3.54
Rel Volume0.19
Avg Volume5.30M
Volume111,308

Performance

Perf Week1.06%
Perf Month-15.09%
Perf Quarter-47.05%
Perf Half Y-60.03%
Perf YTD-34.47%
Perf Year-41.90%
Perf 3Y-91.97%
Perf 5Y-88.61%
Perf 10Y-
Recom1.40
Target Price11.75
Prev Close1.45
Price1.43
Change %-1.03%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 10, 2025ResumedJJefferiesBuy$14+875.6%
Dec 20, 2024DowngradeEEvercore ISIOutperform → In-line$15 → $6+318.1%
Dec 19, 2024DowngradeWWells FargoOverweight → Equal Weight$12 → $6+318.1%
Oct 10, 2024InitiatedUUBSBuy$10+596.9%
Feb 05, 2024InitiatedJJefferiesBuy$36+2,408.7%
Nov 29, 2023InitiatedWWilliam BlairOutperform$38+2,548.1%
Oct 24, 2023InitiatedCCantor FitzgeraldOverweight$40+2,687.5%
Oct 19, 2023InitiatedSStifelBuy$31+2,060.3%
Sep 05, 2023InitiatedCCitigroupBuy$22+1,433.1%
Jul 18, 2023InitiatedGGuggenheimBuy$34+2,269.3%

Peers

Mkt cap
TickerCompanyMkt cap
KYTXKyverna Therapeutics Inc318.49M
ARTVArtiva Biotherapeutics Inc201.19M
ALLOAllogene Therapeutics Inc312.93M
FATEFate Therapeutics Inc212.14M
IPSCCentury Therapeutics Inc306.02M
RNACCartesian Therapeutics Inc210.98M
AUTLAutolus Therapeutics plc ADR335.36M
NKTXNkarta Inc98.19M
SANASana Biotechnology Inc720.32M
CRBUCaribou Biosciences Inc41.86M

Insider trading

8 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Chang David J.Chief Medical OfficerJan 21 '26Buy2.268,80019,8888,800Jan 21 06:56 PM
Binder GwendolynPresident, Science & Tech.Jan 21 '26Buy2.1911,31224,76331,312Jan 21 06:56 PM
Tomasello ShawnDirectorJan 21 '26Buy2.2122,72550,32222,725Jan 21 06:55 PM
Gavel SteveChief Commercial OfficerJan 21 '26Buy2.2722,17050,21522,170Jan 21 06:55 PM
Bollard CatherineDirectorJan 21 '26Buy2.274,4059,9825,405Jan 21 06:54 PM
Nichtberger StevenPresident & CEOJan 21 '26Buy2.2445,000100,7781,031,483Jan 21 06:54 PM
Simon MarkDirectorJan 21 '26Buy2.2811,06125,261147,205Jan 21 06:53 PM
Gerard MichaelGeneral CounselJan 21 '26Buy2.276,60014,9796,600Jan 21 06:53 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IBBiShares Biotechnology ETFAUM: 11.36B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
DFASU.S. Small Cap Portfolio-ETF Class Shares-

News

latest 14 of 206
  • Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases (GlobeNewswire)
  • Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) -9.86%
  • Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Cabaletta Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Loading…
  • Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts (BioPharma Dive) +8.18%
  • Cabaletta Bio to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.11%
  • Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • FDA Clears Imvivas Dual-Target CAR-T for Autoimmune Diseases (Exec Edge) -5.59%
  • Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress (GlobeNewswire)
  • Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting (GlobeNewswire)
  • Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering (GlobeNewswire) +30.27%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.280-0.317-0.2800.000.009
2026Q22026-08-13-0.340-0.373-0.3380.000.009
2026Q12026-05-14-0.390-0.400-0.3880.000.009
2025Q42026-03-23-0.400-0.461-0.4170.000.009
2025Q32025-11-10-0.440-0.472-0.4390.000.009
2025Q22025-08-07-0.730-0.650-0.7290.004.1710
2025Q12025-05-14-0.710-0.654-0.7080.000.008
2024Q42025-03-31-0.650-0.639-0.6500.000.0011
2024Q32024-11-14-0.620-0.596-0.6190.000.0011
2024Q22024-08-08-0.560-0.548-0.5580.000.0010
2024Q12024-05-15-0.510-0.475-0.5080.000.0010
2023Q42024-03-21-0.460-0.393-0.4700.000.0010
2023Q32023-11-09-0.370-0.404-0.3740.000.008
2023Q22023-08-10-0.370-0.440-0.3700.000.005
2023Q12023-05-11-0.450-0.480-0.4470.000.006
2022Q42023-03-16-0.520-0.468-0.5330.000.006

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-4.070-6.175-0.9270.000.00
2020FY-1.440-1.410-1.4400.000.00
2021FY-1.800-1.883-1.7990.000.00
2022FY-1.810-1.747-1.8050.000.00
2023FY-1.650-1.609-1.6530.000.00
2024FY-2.340-2.339-2.3400.000.00
2025FY-2.100-2.189-2.1030.000.00
2026FY--1.255--0.00
2027FY--1.057--0.00
2028FY--0.955--56.34
2029FY--0.699--310.46
2030FY-0.346--744.02

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-056000.000.000.00
2026Q4S2026-08-136000.000.000.00
2026Q4S2026-06-126000.000.000.00
2026Q4S2026-05-145000.000.000.00
2026Q4S2026-03-315000.000.000.00
2026Q4S2026-03-234000.000.000.00
2026Q4S2025-11-115000.000.000.00
2026Q4S2025-11-105000.000.000.00
2026Q4S2025-11-093000.000.000.00
2026Q4S2025-11-083000.000.000.00
2026Q4S2025-11-073000.000.000.00
2026Q4S2025-11-063000.000.000.00
2026Q4S2025-11-053000.000.000.00
2026Q4R2026-11-05320-0.27-0.30-0.25

Estimate history

EPS, annual-0.01-0.508-0.927-1.44-1.799-1.805-1.653-2.34-2.101-1.4272
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.619-0.65-0.708-0.729-0.439-0.417-0.388-0.338-0.284
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual24.03424.03424.03424.06328.92729.44547.82350.743100.479215.72
Period201720182019202020212022202320242025MRQ
Shares, quarterly48.8550.74350.74391.45296.265100.479111.325167.727215.72
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A1.401.654.811.433.680.730.350.100.00
Gross Profit-1.40-1.65-4.81-1.43-3.68-0.73-0.35-0.100.00
Selling, General and Administrative Excl. Other192.23170.59120.3373.2350.4545.5833.4818.586.19
Research and Development165.12142.6797.2055.4239.3032.4921.3811.674.47
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-193.63-172.24-125.14-74.66-54.14-46.31-33.83-18.68-6.19
Interest Expense2.222.000.750.000.000.000.000.00-
Unusual Expense0.000.000.000.000.000.000.000.006.24
Net Income Before Taxes-189.50-167.86-115.86-67.67-52.98-46.29-33.34-16.94-12.20
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-189.50-167.86-115.86-67.67-52.98-46.29-33.34-16.94-12.20
Net Income From Continuing Operations-189.50-167.86-115.86-67.67-52.98-46.29-33.34-16.94-12.20
Net Income-189.50-167.86-115.86-67.67-52.98-46.29-33.34-22.27-12.20
EPS (Recurring)-1.01-2.10-2.34-1.65-1.81-1.80-1.44-0.93-0.33
EPS (Basic, Before Extraordinaries)-1.43-2.10-2.34-1.65-1.81-1.80-1.44-0.93-0.51
EPS (Diluted)-1.43-2.10-2.34-1.65-1.81-1.80-1.44-0.93-0.51
EBITDA-192.23-170.59-120.33-73.23-50.45-45.58-33.48-18.58-6.19
Non-Operating Income (Expense)6.356.3910.036.991.160.020.491.740.23
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense20.2820.9419.4611.346.905.804.392.300.61
Shares Outstanding215.72100.4850.7447.8229.4528.9324.0624.0324.03
Market Capitalization312.79312.79110.95972.68269.55107.38300.21335.75336.24

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.350.370.340.350.340.470.480.47
Gross Profit-0.35-0.37-0.34-0.35-0.34-0.47-0.48-0.47
Selling, General and Administrative Excl. Other54.3651.6543.9642.2646.2445.4436.6533.32
Research and Development47.1444.4337.3536.1939.8237.6429.0225.53
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-54.71-52.02-44.30-42.61-46.59-45.91-37.14-33.78
Interest Expense0.510.520.640.560.580.570.290.75
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-53.05-51.02-43.52-41.92-44.87-45.13-35.94-32.59
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-53.05-51.02-43.52-41.92-44.87-45.13-35.94-32.59
Net Income From Continuing Operations-53.05-51.02-43.52-41.92-44.87-45.13-35.94-32.59
Net Income-53.05-51.02-43.52-41.92-44.87-45.13-35.94-32.59
EPS (Recurring)-0.28-0.34-0.39-0.42-0.44-0.73-0.71-0.65
EPS (Basic, Before Extraordinaries)-0.28-0.34-0.39-0.42-0.44-0.73-0.71-0.65
EPS (Diluted)-0.28-0.34-0.39-0.42-0.44-0.73-0.71-0.65
EBITDA-54.36-51.65-43.96-42.26-46.24-45.44-36.65-33.32
Non-Operating Income (Expense)2.171.521.421.252.311.351.491.95
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.265.505.264.265.825.715.165.41
Shares Outstanding215.72167.73111.32100.4896.2791.4550.7450.74
Market Capitalization312.79507.10299.46210.82214.03136.7167.69110.95

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments133.60163.96241.25106.55122.22108.66136.2033.020.00
Short Term Receivables0.000.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets5.272.713.242.292.324.874.350.980.00
Total Current Assets138.87166.68244.49108.83124.54113.53140.5533.990.00
Net Property, Plant & Equipment21.0516.087.457.571.440.890.810.000.00
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets-------0.000.00
Deferred Tax Assets5.193.94-------
Other Assets5.162.291.710.560.360.300.100.180.00
Total Assets170.28188.98253.65116.97126.34114.72141.4734.170.00
Short Term Debt Incl. Current Port. of LT Debt24.229.973.562.180.000.000.000.000.00
Accounts Payable6.644.924.552.462.331.240.920.600.19
Other Current Liabilities19.3012.197.894.856.053.942.230.340.06
Total Current Liabilities50.1527.0915.999.498.385.183.150.940.25
Long Term Debt2.885.621.462.960.000.000.0043.920.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities5.193.94-------
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities58.2336.6517.4512.458.385.183.1544.860.25
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity112.05152.34236.20104.52117.96109.54138.32-10.69-0.25
Total Shareholders Equity112.05152.34236.20104.52117.96109.54138.32-10.69-0.25
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity112.05152.34236.20104.52117.96109.54138.32-10.69-0.25
Total Liabilities & Stockholders Equity170.28188.98253.65116.97126.34114.72141.4734.170.00
Book Value Per Share1.123.004.943.554.084.555.76-0.44-0.01
Tangible Book Value Per Share1.123.004.943.554.084.555.76-0.44-0.01
Full-Time Employees15616110360543422--
Price to Book Ratio1.100.645.883.130.932.742.43-12.89-
Return on Assets-93.45-52.35-36.52-43.55-38.40-26.03-19.29-71.41-
Return on Equity-126.98-59.64-39.72-47.62-40.69-26.90-26.55--
Return on Invested Capital-146.05-73.35-28.48-49.29-39.24-30.43-12.25-36.72-
Quick Ratio2.776.1515.2911.4714.8621.9244.6636.050.00
Current Ratio2.776.1515.2911.4714.8621.9244.6636.050.00

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-189.50-167.86-115.86-67.67-52.98-46.29-33.34-16.94-12.20
Depreciation1.401.654.811.433.680.730.350.10-
Other Funds (Non Cash)37.0735.5121.2212.607.215.874.512.308.01
Funds from Operations-151.03-130.70-89.83-53.65-42.08-39.69-28.48-14.54-4.20
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-11.13-0.381.610.10-4.305.581.71-1.51-0.46
Cash from Operating Activities-162.16-131.08-88.22-53.55-46.38-34.11-26.77-16.05-4.66
Capital Expenditures-0.35-1.23-2.21-0.69-2.45-1.17-0.64-0.690.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments100.96-49.0449.50-21.76-24.767.17-7.350.000.00
Purchase of Investments0.00-99.040.00-84.26-49.760.00-11.100.000.00
Sale Or Maturity of Investments100.9650.0049.5062.5025.007.173.750.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities100.61-50.2747.29-22.45-27.226.00-7.98-0.690.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock313.70106.6112.57187.6332.9848.90-0.02119.9225.14
Repurchase of Common Pref Stock0.000.000.000.000.000.00-0.190.000.00
Sale of Common Pref Stock313.70106.6112.57187.6332.9848.900.17119.9225.14
Proceedsfrom Stock Options313.46106.3212.30187.5232.9148.830.14119.9225.14
Issuance or Reduction of Debt, Net-12.93-6.26-0.900.000.000.000.000.0012.54
Change in Long Term Debt-12.93-6.26-0.900.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt-12.93-6.26-0.900.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities300.77100.3511.68187.6332.9848.90-0.02119.9237.68
Exchange Rate Effect-0.050.02-0.02------
Net Change in Cash239.18-80.98-29.28111.63-40.6220.79-34.77103.1933.02
Free Cash Flow-162.51-132.31-90.43-54.24-48.83-35.27-27.41-16.74-4.66
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00-0.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments299.38225.10116.64133.60159.93194.68
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets10.465.935.685.274.633.73
Total Current Assets309.85231.03122.32138.87164.56198.41
Net Property, Plant & Equipment18.0819.4920.5621.0521.5923.59
Total Investments and Advances0.000.000.000.000.000.00
Deferred Tax Assets---5.19--
Other Assets8.576.215.275.163.612.50
Total Assets336.49256.73148.15170.28189.76224.50
Short Term Debt Incl. Current Port. of LT Debt17.9319.4923.1224.2221.2220.41
Accounts Payable9.045.816.386.648.277.19
Other Current Liabilities20.3514.6112.0119.3016.2513.93
Total Current Liabilities47.3339.9141.5150.1545.7341.54
Long Term Debt5.246.223.332.884.564.48
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---5.19--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities52.5746.1344.8458.2350.2946.02
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity283.92210.59103.31112.05139.47178.48
Total Shareholders Equity283.92210.59103.31112.05139.47178.48
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity283.92210.59103.31112.05139.47178.48
Total Liabilities & Stockholders Equity336.49256.73148.15170.28189.76224.50
Book Value Per Share1.321.260.931.121.451.95
Tangible Book Value Per Share1.321.260.931.121.451.95
Full-Time Employees--156156148-
Price to Book Ratio1.103.352.411.511.200.63
Return on Assets-72.02-75.36-111.99-93.45-80.43-65.30
Return on Equity-89.52-93.20-156.03-126.98-101.06-76.34
Return on Invested Capital-18.35-23.53-40.81-36.47-31.15-24.67
Quick Ratio6.555.792.952.773.604.78
Current Ratio6.555.792.952.773.604.78

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-53.05-51.02-43.52-41.92-44.87-45.13
Depreciation0.350.370.340.350.340.47
Other Funds (Non Cash)9.589.669.997.849.8010.17
Funds from Operations-43.12-40.98-33.19-33.73-34.72-34.49
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.38-0.53-9.37-1.610.214.07
Cash from Operating Activities-42.74-41.51-42.56-35.34-34.51-30.43
Capital Expenditures-0.140.000.00-0.20-0.08-0.16
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.0050.9650.00-50.00-49.03
Purchase of Investments0.000.000.000.00-50.00-49.03
Sale Or Maturity of Investments0.000.0050.9650.000.00-
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.140.0050.9649.80-50.08-49.20
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock121.11152.8129.5410.24-0.0196.38
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock121.11152.8129.5410.24-0.0196.38
Proceedsfrom Stock Options121.01159.7122.5710.16-0.0396.18
Issuance or Reduction of Debt, Net-3.93-2.82-4.27-1.91-0.80-3.00
Change in Long Term Debt-3.93-2.82-4.27-1.91-0.80-3.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-3.93-2.82-4.27-1.91-0.80-3.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities117.19149.9925.278.33-0.8193.37
Exchange Rate Effect-0.02-0.01-0.01-0.01-0.010.03
Net Change in Cash74.28108.4733.6522.78-85.4113.78
Free Cash Flow-42.89-41.51-42.56-35.55-34.59-30.59

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-30-38.4M-5.18M
2026-10-1526.21%39.3M149.9M4.76M
2026-09-3029.01%38.6M133.1M4.85M
2026-09-1525.03%33.3M133.1M5.11M
2026-08-3127.65%41.4M149.9M4.62M
2026-08-1428.55%42.8M149.9M4.31M
2026-07-3127.85%40.8M146.4M4.96M
2026-07-1528.72%41.0M142.8M4.98M
2026-06-3023.86%34.1M142.8M4.24M
2026-06-1518.38%26.2M142.8M3.30M
2026-05-2916.07%22.9M142.8M3.01M
2026-05-1516.00%22.8M142.8M3.12M
2026-04-3014.45%20.6M142.8M2.34M
2026-04-1520.15%19.6M97.5M3.05M
2026-03-3120.48%20.0M97.5M3.05M
2026-03-1322.59%19.0M84.3M2.98M
2026-02-2722.11%18.6M84.3M3.05M
2026-02-1322.09%18.6M84.3M2.87M
2026-01-3022.15%18.7M84.3M3.69M
2026-01-1521.87%18.4M84.3M3.09M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.601.600.970.0003190.000.0000.0000.000
call1.000.051.050.5212.57981.000.000.880-0.0310.000
call1.500.000.400.154.8121,1530.000.686-0.0300.001
call2.000.000.100.035.3918740.000.531-0.0260.001
call2.500.000.100.053.5291,8740.000.258-0.0140.001
call3.000.000.100.014.1527410.000.234-0.0150.001
call3.500.000.050.253.8342270.000.139-0.0100.001
call4.000.000.150.054.2101740.000.130-0.0110.001
call4.500.001.000.054.53023.000.000.124-0.0110.000
call5.000.000.500.054.80835.000.000.120-0.0120.000
call5.500.000.200.065.0541,0140.000.116-0.0120.000
call7.500.001.000.005.8190.000.000.107-0.0130.000
put0.500.001.000.2514.06710.000.00-0.053-0.0180.000
put1.000.001.000.006.5290.000.00-0.189-0.0210.001
put1.500.001.000.0512.10152.000.00-0.305-0.0300.001
put2.000.051.050.457.25084.000.00-0.696-0.0120.001
put2.500.951.751.188.1982570.00-0.743-0.0150.001
put3.001.102.101.749.72432.000.00-0.766-0.0150.001
put3.501.552.551.128.8600.000.00-0.861-0.0110.001
put4.002.103.101.589.32311.000.00-0.869-0.0110.000
put4.502.603.602.099.71824.000.00-0.875-0.0120.000
put5.003.104.102.4210.06222.000.00-0.880-0.0120.000
put5.503.604.600.0010.4190.000.00-0.883-0.0120.000
put7.505.606.600.0011.3620.000.00-0.893-0.0130.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-098-KCurrent report2026-11-09SEC
2026-11-06SCHEDULE 13G/ASEC
2026-11-06SCHEDULE 13G/ASEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-30SCHEDULE 13G/ASEC
2026-10-27SCHEDULE 13G/ASEC
2026-09-148-KCurrent report2026-09-14SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-12SCHEDULE 13GSEC
2026-08-12SCHEDULE 13G/ASEC
2026-07-31SCHEDULE 13GSEC
2026-07-27SCHEDULE 13GSEC
2026-07-23SCHEDULE 13G/ASEC
2026-06-118-KCurrent report2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-05SCHEDULE 13G/ASEC
2026-06-04SCHEDULE 13G/ASEC
2026-06-038-KCurrent report2026-06-03SEC
2026-06-01DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-01296.19K800
2025-120000
2025-110000

Institutional holders

Manager% owned
JENNISON ASSOCIATES LLC12.29%
T. Rowe Price Investment Management, Inc.11.57%
Bain Capital Life Sciences Investors, LLC10.57%
BlackRock, Inc.6.60%
ADAGE CAPITAL PARTNERS GP, L.L.C.5.63%
STATE STREET CORP4.81%
VANGUARD CAPITAL MANAGEMENT LLC4.43%
PRICE T ROWE ASSOCIATES INC /MD/2.71%
Woodline Partners LP2.58%
GEODE CAPITAL MANAGEMENT, LLC2.52%

Funds

Fund% owned
T. Rowe Price Small-Cap Value Fund, Inc.4.82%
State Street(R) SPDR(R) S&P(R) Biotech ETF3.22%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.20%
PGIM Jennison Health Sciences Fund2.93%
iShares Russell 2000 ETF1.79%
PGIM Jennison Small Company Fund1.65%
VANGUARD EXTENDED MARKET INDEX FUND1.15%
T. Rowe Price Health Sciences Fund, Inc.1.10%
T. Rowe Price Small-Cap Stock Fund, Inc.0.85%
T. Rowe Price New Horizons Fund, Inc.0.84%

OakChart. CABA. Cached 15 minutes.